NAGE · Niagen Bioscience Inc. Common Stock
View on chartInsiders & Stakes
| Hoi Shuen Solina Holly Chau 10% Owner | ▲ Buy | Open Market | 19,294,356 Shares held | 8/20/2024 | View profile |
| Champion River Ventures Ltd Director | ▲ Buy | Open Market | 11,408,715 Shares held | 9/6/2023 | View profile |
| Robert N. Fried CEO | ▲ Buy | Grant | 1,060,087 Shares held | 6/30/2026 | View profile |
| Frank L. Jaksch Jr. Director | ▼ Sell | Open Market | 244,179 Shares held | 12/13/2024 | View profile |
| Gerber Brianna Chief Financial Officer | ▲ Buy | Open Market | 27,436 Shares held | 12/1/2023 | View profile |
| Ozan Pamir Chief Financial Officer | ▲ Buy | Grant | 11,627 Shares held | 6/30/2026 | View profile |
| Steven D. Rubin Director | ▲ Buy | Open Market | 7,000 Shares held | 5/25/2023 | View profile |
| Carlos Luis Lopez SVP, General Counsel | ▲ Buy | Grant | 4,565 Shares held | 6/30/2026 | View profile |
| Kristin Patrick Director | ▼ Sell | Open Market | 0 Shares held | 8/23/2024 | View profile |
| Ka Shing Li | ▼ Sell | Open Market | 0 Shares held | 8/20/2024 | View profile |
Transaction History
| Carlos Luis Lopez | ▲ Buy | Grant | 2,314 | $6K | 6/30/2026 |
| Ozan Pamir | ▲ Buy | Grant | 4,255 | $12K | 6/30/2026 |
| Robert N. Fried | ▲ Buy | Grant | 1,106 | $3K | 6/30/2026 |
| Robert N. Fried | ▲ Buy | Option Exercise | 20,000 | $52K | 4/24/2026 |
| Ozan Pamir | ▲ Buy | Open Market | 4,465 | $30K | 11/14/2025 |
| Ozan Pamir | ▲ Buy | Open Market | 2,220 | $15K | 11/14/2025 |
| Robert N. Fried | ▲ Buy | Option Exercise | 66,667 | $220K | 4/9/2025 |
| Carlos Luis Lopez | ▲ Buy | Open Market | 273 | $2K | 3/7/2025 |
| Frank L. Jaksch Jr. | ▲ Buy | Option Exercise | 50,001 | $183K | 12/13/2024 |
| Frank L. Jaksch Jr. | ▼ Sell | Open Market | 37,161 | $230K | 12/13/2024 |
| Ozan Pamir | ▲ Buy | Open Market | 2,907 | $21K | 11/22/2024 |
| Kristin Patrick | ▲ Buy | Option Exercise | 3,000 | $5K | 8/23/2024 |
| Kristin Patrick | ▲ Buy | Option Exercise | 20,000 | $33K | 8/23/2024 |
| Kristin Patrick | ▼ Sell | Open Market | 23,000 | $82K | 8/23/2024 |
| Ka Shing Li | ▼ Sell | Open Market | 11,408,715 | — | 8/20/2024 |
| Hoi Shuen Solina Holly Chau | ▲ Buy | Open Market | 11,408,715 | — | 8/20/2024 |
| Gerber Brianna | ▲ Buy | Open Market | 5,000 | $7K | 12/1/2023 |
| Champion River Ventures Ltd | ▲ Buy | Open Market | 3,467,778 | — | 9/6/2023 |
| Gerber Brianna | ▲ Buy | Option Exercise | 22,436 | — | 8/12/2023 |
| Frank L. Jaksch Jr. | ▲ Buy | Open Market | 7,000 | $12K | 6/12/2023 |
| Robert N. Fried | ▲ Buy | Open Market | 7,000 | $10K | 5/31/2023 |
| Steven D. Rubin | ▲ Buy | Open Market | 7,000 | $10K | 5/25/2023 |
| Robert N. Fried | ▲ Buy | Open Market | 80,000 | $100K | 9/30/2022 |
| Hoi Shuen Solina Holly Chau | ▲ Buy | Open Market | 960,000 | $1.2M | 9/30/2022 |
| Hoi Shuen Solina Holly Chau | ▲ Buy | Open Market | 60,037 | $100K | 6/16/2022 |
| Robert N. Fried | ▲ Buy | Open Market | 25,000 | $54K | 3/16/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
NAGE linked to new preclinical study on CD38 and NAD+ decline
A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.
NAGE linked to new preclinical study on CD38 and NAD+ decline. A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.